Years of life lost and mortality rates from metastatic prostate cancer in contemporary African Americans vs. Caucasians

Introduction It is unknown whether the historical survival disadvantage of African American metastatic prostate cancer (mPCa) patients persists in abiraterone and androgen receptor pathway inhibitors (ARPIs) eras. Methods In Surveillance, Epidemiology, and End Results (SEER) database (2017–2021), Af...

Full description

Saved in:
Bibliographic Details
Published in:World journal of urology 2026-02, Vol.44 (1), p.189, Article 189
Main Authors: Quarta, Leonardo, Nicolazzini, Michele, Catanzaro, Calogero, Polverino, Federico, Petix, Michele, Filzmayer, Maximilian, Lee, Nick J., Goyal, Jordan A., Volpe, Alessandro, Schiavina, Riccardo, Longo, Nicola, Carmignani, Luca, Chun, Felix K. H., Shariat, Shahrokh F., Barletta, Francesco, Stabile, Armando, Gandaglia, Giorgio, Montorsi, Francesco, Saad, Fred, Briganti, Alberto, Karakiewicz, Pierre I.
Format: Article
Language:English
Subjects:
African Americans
Age
Androgen receptors
Androgens
Epidemiology
Ethnicity
Life tables
Low income groups
Medical diagnosis
Medicine
Medicine & Public Health
Metastases
Metastasis
Monte Carlo simulation
Mortality
Nephrology
Oncology
Patients
Prostate cancer
Regression analysis
Surveillance
Urology
White people
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!